Latest News
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).Plants produce many substances with promising pharmacological activities. For example, Rhododendron species produce a class of compounds, called orsellinic acid-derived meroterpenoids, with remarkable anticancer, anti-HIV, antidiabetic and anti-inflammatory activities.
PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with impaired DNA repair.
Their study, published in Journal of Medical Internet Research, found perceived effectiveness - reductions in weight, appetite or food cravings - was the strongest predictor of satisfaction and intention to continue treatment, regardless of side effects.
Pfizer Inc. (NYSE: PFE) announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. The program provides Americans a wide range of more than 30 medicines at a significant discount off list prices.
On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of €1 billion.
On February 2, 2026, Sanofi entered a mandate with an investment service provider for this program. Under the terms of the mandate, Sanofi will repurchase its own shares for a total consideration of up to €1 billion, between February 3, 2026, and December 31, 2026, at the latest(1).
AstraZeneca today begins trading its ordinary shares on the New York Stock Exchange (NYSE) for the first time, enabling more US investors to participate in the Company’s strong growth. With this change the trading of AstraZeneca ordinary shares is now aligned across the NYSE, the London Stock Exchange (LSE) and Nasdaq Stockholm (STO) under a harmonised listing structure.In the paper, the University of Minnesota Medical School research team provides information about metformin and summarizes several studies in low, standard and high risk populations
The researchers report that chemotherapy-induced damage to the intestinal lining alters nutrient availability for gut bacteria, reshaping the microbiota and increasing the production of
